Masimo Corporation (NASDAQ:MASI) Given Consensus Recommendation of “Hold” by Brokerages

Masimo Corporation (NASDAQ:MASI) has earned an average rating of “Hold” from the eight analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $189.40.

A number of analysts have recently weighed in on the stock. Bank of America assumed coverage on shares of Masimo in a research report on Monday, November 17th. They set a “neutral” rating and a $162.00 price target for the company. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $190.00 price target on shares of Masimo in a research report on Friday, December 5th.

Institutional Investors Weigh In On Masimo

A number of institutional investors have recently made changes to their positions in MASI. Vanguard Group Inc. raised its position in shares of Masimo by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,810,011 shares of the medical equipment provider’s stock valued at $709,717,000 after acquiring an additional 171,876 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Masimo by 1.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,663,875 shares of the medical equipment provider’s stock valued at $346,464,000 after purchasing an additional 43,915 shares during the last quarter. State Street Corp increased its stake in Masimo by 0.7% during the second quarter. State Street Corp now owns 1,486,394 shares of the medical equipment provider’s stock valued at $250,041,000 after purchasing an additional 10,403 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Masimo by 20.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,419,250 shares of the medical equipment provider’s stock worth $209,410,000 after purchasing an additional 238,047 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in shares of Masimo by 21.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,381,085 shares of the medical equipment provider’s stock worth $203,779,000 after buying an additional 246,595 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Trading Down 1.8%

NASDAQ:MASI opened at $136.62 on Thursday. The stock has a market cap of $7.34 billion, a price-to-earnings ratio of -12.96, a price-to-earnings-growth ratio of 1.41 and a beta of 1.26. Masimo has a one year low of $125.94 and a one year high of $194.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.92 and a current ratio of 2.84. The business’s 50-day simple moving average is $137.56 and its 200 day simple moving average is $144.01.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 4th. The medical equipment provider reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.12. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%.The company had revenue of $371.20 million for the quarter, compared to the consensus estimate of $366.89 million. During the same period in the previous year, the business earned $0.86 EPS. Masimo’s revenue for the quarter was up 8.2% compared to the same quarter last year. As a group, sell-side analysts predict that Masimo will post 4.1 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.